Loading organizations...
§ Private Profile · Marseille, Provence-Alpes-Cote d'Azur, France
Develops immuno-oncology diagnostic tests for cancer treatment decisions, focusing on tumor immune contexture and prognostic biomarkers.
HalioDx, based in Marseille, France, developed immuno-oncology diagnostic tests to analyze tumor immune contexture and guide cancer treatment decisions. The company focused on prognostic and predictive biomarkers, notably the Immunoscore, which assesses relapse risk in colon cancer by measuring CD3 and CD8 T cells in tumor samples. They provided immune-based products and services to oncologists and biopharma drug developers for precision medicine in immunotherapy and combination therapies. Prior to its acquisition, HalioDx raised a total of $31.26 million from investors including Bpifrance, Capricorn Venture Partners, and Amundi, and employed approximately 75 individuals. It was acquired by Veracyte for approximately $318 million (€260 million cash-and-stock) in June 2021. HalioDx was founded in 2014 by Vincent Fert and Jérôme Galon.
HalioDx has raised $22.6M across 1 funding round.
HalioDx has raised $22.6M in total across 1 funding round.
HalioDx has raised $22.6M across 1 funding round. Most recently, it raised $22.6M Series B in January 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 17, 2018 | $22.6M Series B | — | BNP Paribas Développement, MI Care, PSIM Fund, Quest For Growth, Sham Innovation Sant, Sofipaca | Announced |
HalioDx has raised $22.6M in total across 1 funding round.
HalioDx's investors include BNP Paribas Développement, MI Care, PSIM Fund, Quest for Growth, Sham Innovation Sant, Sofipaca.